FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069035823> ?p ?o ?g. }

• W2069035823 endingPage "946" @default.
• W2069035823 startingPage "939" @default.
• W2069035823 abstract "IntroductionTo compare the impact on overall survival (OS) of docetaxel-based chemotherapy versus vinca alkaloid–based regimens for first-line therapy of advanced non-small cell lung cancer.MethodsA meta-analysis of all randomized, controlled trials comparing docetaxel- and vinca alkaloid–based chemotherapy was undertaken using MEDLINE, CANCERLIT, MEDSCAPE, Google Scholar, the Cochrane Library, the National Institutes of Health randomized, controlled trials register, and conference proceedings, supplemented by information from clinical study reports. All published and unpublished randomized, controlled trials (in any language) were included. Analysis was based on pooling individual logarithms of the hazard ratio for OS and the odds ratio (OR) for safety.ResultsFrom eight potentially eligible trials, seven were selected (n = 2867). Docetaxel was administered with a platinum agent (three trials), with gemcitabine (two trials), or as monotherapy (two trials). Vinca alkaloid (vinorelbine [six trials] and vindesine [one trial]) was administered with cisplatin (six trials) or alone (one trial). The pooled estimate for OS showed an 11% improvement in favor of docetaxel (hazard ratio = 0.89; 95% confidence interval: 0.82–0.96; p = 0.004). Sensitivity analyses considering only vinorelbine as a comparator or only the doublet regimens showed similar improvements. Grade 3/4 neutropenia and grade 3/4 serious adverse events were less frequent with docetaxel- versus vinca alkaloid–based regimens (OR = 0.59; 95% confidence interval: 0.38–0.89; p = 0.013 and OR = 0.68; 95% confidence interval: 0.55–0.84; p < 0.001, respectively).ConclusionAccording to this meta-analysis, docetaxel is superior to vinca alkaloid–based regimens in terms of OS and safety for first-line therapy of advanced non-small cell lung cancer. To compare the impact on overall survival (OS) of docetaxel-based chemotherapy versus vinca alkaloid–based regimens for first-line therapy of advanced non-small cell lung cancer. A meta-analysis of all randomized, controlled trials comparing docetaxel- and vinca alkaloid–based chemotherapy was undertaken using MEDLINE, CANCERLIT, MEDSCAPE, Google Scholar, the Cochrane Library, the National Institutes of Health randomized, controlled trials register, and conference proceedings, supplemented by information from clinical study reports. All published and unpublished randomized, controlled trials (in any language) were included. Analysis was based on pooling individual logarithms of the hazard ratio for OS and the odds ratio (OR) for safety. From eight potentially eligible trials, seven were selected (n = 2867). Docetaxel was administered with a platinum agent (three trials), with gemcitabine (two trials), or as monotherapy (two trials). Vinca alkaloid (vinorelbine [six trials] and vindesine [one trial]) was administered with cisplatin (six trials) or alone (one trial). The pooled estimate for OS showed an 11% improvement in favor of docetaxel (hazard ratio = 0.89; 95% confidence interval: 0.82–0.96; p = 0.004). Sensitivity analyses considering only vinorelbine as a comparator or only the doublet regimens showed similar improvements. Grade 3/4 neutropenia and grade 3/4 serious adverse events were less frequent with docetaxel- versus vinca alkaloid–based regimens (OR = 0.59; 95% confidence interval: 0.38–0.89; p = 0.013 and OR = 0.68; 95% confidence interval: 0.55–0.84; p < 0.001, respectively). According to this meta-analysis, docetaxel is superior to vinca alkaloid–based regimens in terms of OS and safety for first-line therapy of advanced non-small cell lung cancer." @default.
• W2069035823 created "2016-06-24" @default.
• W2069035823 creator A5009466654 @default.
• W2069035823 creator A5017495356 @default.
• W2069035823 creator A5020949450 @default.
• W2069035823 creator A5034162457 @default.
• W2069035823 creator A5041989947 @default.
• W2069035823 creator A5059713827 @default.
• W2069035823 creator A5066167770 @default.
• W2069035823 creator A5074857320 @default.
• W2069035823 creator A5084377238 @default.
• W2069035823 creator A5088533098 @default.
• W2069035823 date "2007-10-01" @default.
• W2069035823 modified "2023-09-27" @default.
• W2069035823 title "Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of Seven Randomized Clinical Trials" @default.
• W2069035823 cites W1837121308 @default.
• W2069035823 cites W1907932102 @default.
• W2069035823 cites W1935885922 @default.
• W2069035823 cites W1975081329 @default.
• W2069035823 cites W1986215651 @default.
• W2069035823 cites W1996761484 @default.
• W2069035823 cites W2020830322 @default.
• W2069035823 cites W2032332769 @default.
• W2069035823 cites W2037139573 @default.
• W2069035823 cites W204046373 @default.
• W2069035823 cites W2050119069 @default.
• W2069035823 cites W2054100499 @default.
• W2069035823 cites W2059563719 @default.
• W2069035823 cites W2075642745 @default.
• W2069035823 cites W2076107896 @default.
• W2069035823 cites W2079913462 @default.
• W2069035823 cites W2095992216 @default.
• W2069035823 cites W2098158939 @default.
• W2069035823 cites W2099072173 @default.
• W2069035823 cites W2103953671 @default.
• W2069035823 cites W2116036495 @default.
• W2069035823 cites W2127405377 @default.
• W2069035823 cites W2129793485 @default.
• W2069035823 cites W2139730244 @default.
• W2069035823 cites W2143888113 @default.
• W2069035823 cites W2145653040 @default.
• W2069035823 cites W2147082943 @default.
• W2069035823 cites W2150358925 @default.
• W2069035823 cites W2151522757 @default.
• W2069035823 cites W2155132414 @default.
• W2069035823 cites W2166399931 @default.
• W2069035823 cites W2168708405 @default.
• W2069035823 cites W2171419394 @default.
• W2069035823 cites W2316900837 @default.
• W2069035823 cites W2317126626 @default.
• W2069035823 cites W2600672782 @default.
• W2069035823 cites W4239714259 @default.
• W2069035823 cites W4251309185 @default.
• W2069035823 cites W4317564151 @default.
• W2069035823 doi "https://doi.org/10.1097/jto.0b013e318153fa2b" @default.
• W2069035823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17909357" @default.
• W2069035823 hasPublicationYear "2007" @default.
• W2069035823 type Work @default.
• W2069035823 sameAs 2069035823 @default.
• W2069035823 citedByCount "68" @default.
• W2069035823 countsByYear W20690358232012 @default.
• W2069035823 countsByYear W20690358232013 @default.
• W2069035823 countsByYear W20690358232014 @default.
• W2069035823 countsByYear W20690358232015 @default.
• W2069035823 countsByYear W20690358232016 @default.
• W2069035823 countsByYear W20690358232017 @default.
• W2069035823 countsByYear W20690358232018 @default.
• W2069035823 countsByYear W20690358232019 @default.
• W2069035823 countsByYear W20690358232020 @default.
• W2069035823 crossrefType "journal-article" @default.
• W2069035823 hasAuthorship W2069035823A5009466654 @default.
• W2069035823 hasAuthorship W2069035823A5017495356 @default.
• W2069035823 hasAuthorship W2069035823A5020949450 @default.
• W2069035823 hasAuthorship W2069035823A5034162457 @default.
• W2069035823 hasAuthorship W2069035823A5041989947 @default.
• W2069035823 hasAuthorship W2069035823A5059713827 @default.
• W2069035823 hasAuthorship W2069035823A5066167770 @default.
• W2069035823 hasAuthorship W2069035823A5074857320 @default.
• W2069035823 hasAuthorship W2069035823A5084377238 @default.
• W2069035823 hasAuthorship W2069035823A5088533098 @default.
• W2069035823 hasBestOaLocation W20690358231 @default.
• W2069035823 hasConcept C126322002 @default.
• W2069035823 hasConcept C143998085 @default.
• W2069035823 hasConcept C168563851 @default.
• W2069035823 hasConcept C197934379 @default.
• W2069035823 hasConcept C207103383 @default.
• W2069035823 hasConcept C2776256026 @default.
• W2069035823 hasConcept C2776553716 @default.
• W2069035823 hasConcept C2776694085 @default.
• W2069035823 hasConcept C2776755627 @default.
• W2069035823 hasConcept C2777096885 @default.
• W2069035823 hasConcept C2778239845 @default.
• W2069035823 hasConcept C2779321808 @default.
• W2069035823 hasConcept C2779429289 @default.
• W2069035823 hasConcept C2780350996 @default.
• W2069035823 hasConcept C2781190966 @default.
• W2069035823 hasConcept C44249647 @default.
• W2069035823 hasConcept C535046627 @default.

• next